|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Varespladib>> Market Analysis Reports |
Market Analysis Reports of Varespladib |
|
Global Market Report of VARESPLADIB (CAS 172732-68-2) December 2024 Varespladip (CAS 172732-68-2) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). CAS 172732-68-2 Varespladib Chemical Report & Database ... Consumption Report & Database definitions: Name: Varespladib: Varespladib; [[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy ... -68-2 APPLICATIONS: Chemical or Reaction Intermediate The Varespladib Report & Database gives Market Consumption ... Outlook 2012 - Rising Stars - Innovators Deliver but Rewards Not Guranteed! ... unmet need/niche markets and Varespladib (ANTH) and Blinatumomab (MITI) are ... yet to be partnered. ANTH’s Varespladib offers a high risk reward opportunity ... Intracranial Arterial Diseases - Pipeline Review - 2019 ... ), Vorapaxar (SCH 530348), Canakinumab (ACZ885), Varespladib (A 002), Aliskiren, Generx, Xarelto (rivaroxaban ... ANTHERA PHARMA - Portfolio of More than Just a "Me Too" = Better Commercial Opportunity ... clarity on its lead drugs – Varespladib, ACS and Blisibimod, Lupus ... VISTA-16, design is summarized in Annexure) of Varespladib (formerly A-002, PhIII, Acute ... Syndrome-ACS, unpartnered). Moreover, Varespladib's favorable effect on LDL (44% reduction ... Anthera pharma - What More After VISTA-16 Failure? ... PhII data of its key drug Varespladib (formerly A-002, PhIII, Acute Coronary ... |